Nurix Therapeutics. has been granted a patent for compounds and methods that inhibit the E3 enzyme Cbl-b in the ubiquitin proteasome pathway. These innovations aim to modulate the immune system and treat diseases, including cancer, using combinations of Cbl-b inhibitors with vaccines and oncolytic viruses. GlobalData’s report on Nurix Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nurix Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Nurix Therapeutics's grant share as of July 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12049471B2 encompasses a series of claims related to specific chemical compounds and methods for their synthesis. The primary claim outlines a compound characterized by a defined chemical formula, with subsequent claims detailing variations of this compound, including stereoisomers and specific selections from a defined group. The patent further elaborates on methods for synthesizing these compounds, specifying the use of various bases, solvents, and coupling agents. Notably, the methods include the use of sodium hydride (NaH) in tetrahydrofuran (THF) and a combination of DIPEA, dimethylformamide (DMF), and HATU for amide coupling, among other reagents.
Additional claims describe further steps in the synthesis process, incorporating weak acids like acetic acid and strong acid sources such as trialkylsilyl halides, specifically trimethylsilyl iodide (TMSI). The methods also involve the use of copper(II) halides, such as CuBr2, in acetonitrile (MeCN) as part of the reaction conditions. Overall, the patent presents a comprehensive framework for the development and synthesis of these chemical compounds, which may have potential applications in various fields, including pharmaceuticals and materials science.
To know more about GlobalData’s detailed insights on Nurix Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
